COMPARISON OF DOXORUBICIN WITH CYCLOLEUCINE IN THE TREATMENT OF SARCOMAS

Google Scholar
  • 1 January 1981
    • journal article
    • research article
    • Vol. 65  (1-2) , 21-27
Abstract
In this patient series, doxorubicin and cycloleucine at a dose of 300 mg/kg both show response rates in the treatment of advanced soft tissue sarcomas of about 15%. Lower doses of cycloleucine (200 mg/kg) yielded less toxicity but were less effective against the sarcomas (6% response rate, 3 of 51 patients). There were no complete responses with cycloleucine; there were 3 with doxorubicin. Survival times for patients receiving doxorubicin were significantly longer than those of patients receiving cycloleucine at doses of 300 mg/kg (P < 0.001) or 200 mg/kg (P = 0.02). The estimated survival times were 29 wk for doxorubicin and 21 (300 mg/kg) and 18 (200 mg/kg) wk for cycloleucine. Toxic effects due to cycloleucine were excessive, with severe thrombocytopenia and CNS depression being the most prominent.

This publication has 1 reference indexed in Scilit: